In May 2024, French pharmaceutical giant Sanofi announced a three-way collaboration with Formation Bio and OpenAI to develop AI software for drug research. William Tsai, Sanofi's Head of Public ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi, Formation Bio and OpenAI have jointly designed an AI-powered tool that will be rolled out in the former's phase 3 multiple sclerosis trials. There’s a new Muse in town.

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...